-+ 0.00%
-+ 0.00%
-+ 0.00%

Avacta’s AVA6207 Overcomes Cancer Drug Resistance in Preclinical Studies

PUBT·11/19/2026 07:13:44
Listen to the news
Avacta’s AVA6207 Overcomes Cancer Drug Resistance in Preclinical Studies
  • Avacta presented preclinical results today in Barcelona showing AVA6207 reversed resistance to topoisomerase I inhibitors in laboratory studies and animal models.
  • The dual-payload drug achieved complete responses in resistant ovarian and lung tumor models, supporting clinical development in biomarker-defined patient groups.
  • AVA6207 also outperformed Enhertu in a gastric tumor model.
  • Payloads have been selected, with the clinical candidate moving into studies supporting an investigational new drug application in the fourth quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avacta Group plc published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.